These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37251692)

  • 1. Modified ASO conjugates encapsulated with cytidinyl/cationic lipids exhibit more potent and longer-lasting anti-HCC effects.
    Pan Y; Guan J; Gao Y; Zhu Y; Li H; Guo H; He Q; Guan Z; Yang Z
    Mol Ther Nucleic Acids; 2023 Jun; 32():807-821. PubMed ID: 37251692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity and Tissue Distribution of Antisense Oligonucleotide CT102 Encapsulated with Cytidinyl/Cationic Lipid against Hepatocellular Carcinoma.
    Guan J; Pan Y; Li H; Zhu Y; Gao Y; Wang J; Zhou Y; Guan Z; Yang Z
    Mol Pharm; 2022 Dec; 19(12):4552-4564. PubMed ID: 35508302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural optimization and additional targets identification of antisense oligonucleotide G3139 encapsulated in a neutral cytidinyl-lipid combined with a cationic lipid in vitro and in vivo.
    Ma Y; Zhao W; Li Y; Pan Y; Wang S; Zhu Y; Kong L; Guan Z; Wang J; Zhang L; Yang Z
    Biomaterials; 2019 Mar; 197():182-193. PubMed ID: 30660994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel formulation of c-di-GMP with cytidinyl/cationic lipid reverses T cell exhaustion and activates stronger anti-tumor immunity.
    Yu X; Yu J; Dai H; Deng C; Sun X; Long S; Jiang Z; Jin H; Guan Z; Yang Z
    Theranostics; 2022; 12(15):6723-6739. PubMed ID: 36185614
    [No Abstract]   [Full Text] [Related]  

  • 5. siRNA Packaged with Neutral Cytidinyl/Cationic/PEG Lipids for Enhanced Antitumor Efficiency and Safety
    Zhou X; Pan Y; Li Z; Li H; Wu J; Ma Y; Guan Z; Yang Z
    ACS Appl Bio Mater; 2020 Sep; 3(9):6297-6309. PubMed ID: 35021760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational preparation and application of a mRNA delivery system with cytidinyl/cationic lipid.
    Li L; Long J; Sang Y; Wang X; Zhou X; Pan Y; Cao Y; Huang H; Yang Z; Yang J; Wang S
    J Control Release; 2021 Dec; 340():114-124. PubMed ID: 34699870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective Anti-melanoma Effect of Phosphothioated Aptamer Encapsulated by Neutral Cytidinyl/Cationic Lipids.
    Wu J; Wang S; Li X; Zhang Q; Yang J; Ma Y; Guan Z; Yang Z
    Front Cell Dev Biol; 2021; 9():660233. PubMed ID: 34262898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid nanoparticle delivery limits antisense oligonucleotide activity and cellular distribution in the brain after intracerebroventricular injection.
    Byrnes AE; Dominguez SL; Yen CW; Laufer BI; Foreman O; Reichelt M; Lin H; Sagolla M; Hötzel K; Ngu H; Soendergaard C; Estevez A; Lin HC; Goyon A; Bian J; Lin J; Hinz FI; Friedman BA; Easton A; Hoogenraad CC
    Mol Ther Nucleic Acids; 2023 Jun; 32():773-793. PubMed ID: 37346977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T7 Peptide-Conjugated Lipid Nanoparticles for Dual Modulation of Bcl-2 and Akt-1 in Lung and Cervical Carcinomas.
    Cheng X; Yu D; Cheng G; Yung BC; Liu Y; Li H; Kang C; Fang X; Tian S; Zhou X; Liu Q; Lee RJ
    Mol Pharm; 2018 Oct; 15(10):4722-4732. PubMed ID: 30138565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Annealing novel nucleobase-lipids with oligonucleotides or plasmid DNA based on H-bonding or π-π interaction: Assemblies and transfections.
    Ma Y; Zhu Y; Wang C; Pan D; Liu S; Yang M; Xiao Z; Yang X; Zhao W; Zhou X; Li Y; Pan Y; Sun J; Wang S; Guan Z; Zhang L; Yang Z
    Biomaterials; 2018 Sep; 178():147-157. PubMed ID: 29933101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Grafted with Trastuzumab: A Proof-of-Concept Study in Prostate Cancer.
    Sicard G; Paris C; Giacometti S; Rodallec A; Ciccolini J; Rocchi P; Fanciullino R
    Pharmaceutics; 2020 Nov; 12(12):. PubMed ID: 33260460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of a Quality-By-Design Approach to Optimise Lipid-Polymer Hybrid Nanoparticles Loaded with a Splice-Correction Antisense Oligonucleotide: Maximising Loading and Intracellular Delivery.
    Thanki K; Papai S; Lokras A; Rose F; Falkenberg E; Franzyk H; Foged C
    Pharm Res; 2019 Jan; 36(3):37. PubMed ID: 30623253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of nucleotidyl lipids and their application in the targeted delivery of siG12D for pancreatic cancer therapy.
    Pan Y; Zhu Y; Ma Y; Hong J; Zhao W; Gao Y; Guan J; Ren R; Zhang Q; Yu J; Guan Z; Yang Z
    Biomed Pharmacother; 2024 Mar; 172():116239. PubMed ID: 38325267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization in Chemical Modification of Single-Stranded siRNA Encapsulated by Neutral Cytidinyl/Cationic Lipids.
    Li Z; Wang X; Zhou X; Wang J; Guan Z; Yang Z
    Front Chem; 2022; 10():843181. PubMed ID: 35345539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of cRGD conjugation at 5'-antisense strand of siRNA by phosphodiester linkage extension.
    Zhou X; Pan Y; Yu L; Wu J; Li Z; Li H; Guan Z; Tang X; Yang Z
    Mol Ther Nucleic Acids; 2021 Sep; 25():603-612. PubMed ID: 34589281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation.
    Hvam ML; Cai Y; Dagnæs-Hansen F; Nielsen JS; Wengel J; Kjems J; Howard KA
    Mol Ther; 2017 Jul; 25(7):1710-1717. PubMed ID: 28641935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models.
    Kim Y; Jo M; Schmidt J; Luo X; Prakash TP; Zhou T; Klein S; Xiao X; Post N; Yin Z; MacLeod AR
    Mol Ther; 2019 Sep; 27(9):1547-1557. PubMed ID: 31303442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bolaamphiphile-based nanocomplex delivery of phosphorothioate gapmer antisense oligonucleotides as a treatment for Clostridium difficile.
    Hegarty JP; Krzeminski J; Sharma AK; Guzman-Villanueva D; Weissig V; Stewart DB
    Int J Nanomedicine; 2016; 11():3607-19. PubMed ID: 27536102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides.
    Lo YL; Liu Y
    PLoS One; 2014; 9(3):e90180. PubMed ID: 24637737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allele-specific antisense oligonucleotides for the treatment of BEST1-related dominantly inherited retinal diseases: An in vitro model.
    Karaosmanoglu B; Imren G; Utine E; Taylan Sekeroglu H; Taskiran EZ
    Exp Eye Res; 2024 Apr; 241():109833. PubMed ID: 38369231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.